Curaleaf Launches $83M Share Repurchase Program for 5% of Outstanding Shares
CURLF has more than doubled off its 52-week low of $0.72.
Summary
Curaleaf Holdings, Inc. announced a new share repurchase program, authorizing the buyback of up to $83 million in subordinate voting shares over the next year, representing approximately 5% of its outstanding shares.
Key Events · Financing and Capital Events · CURLF
-
Share Repurchase Program Authorized
The Board of Directors has authorized a Normal Course Issuer Bid (NCIB) to repurchase up to 34,388,831 subordinate voting shares, representing approximately 5% of the shares outstanding as of April 10, 2026.
-
Significant Value of Repurchase
The aggregate fair market value of the shares authorized for repurchase is approximately U.S.$83 million, based on the closing trading price on April 14, 2026.
-
Program Duration and Rationale
The NCIB will commence on April 20, 2026, and end no later than April 19, 2027. Chairman and CEO Boris Jordan stated the program is a 'meaningful way to return value to our shareholders and reflects our confidence in the strength and durability of our strategy,' indicating management believes the shares may be undervalued.
Analysis · CURLF · Life Sciences
Curaleaf Holdings, Inc. has initiated a significant share repurchase program, authorizing the buyback of up to $83 million in subordinate voting shares. This program, representing approximately 5% of the company's outstanding shares, signals strong management confidence in the company's valuation and future strategy. Share repurchases can reduce the number of outstanding shares, potentially boosting earnings per share and supporting the stock price, especially if management believes the shares are undervalued. This move is a direct way to return value to shareholders and could be viewed positively by the market.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 35.3% of the 1324 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CURLF was trading at $2.73 on OTC in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $0.72 to $5.05. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.